Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of 3401 myeloma patients s/p ASCT finds 110 (3.2%) developed 2nd heme malignancy [therapy related myeloid neoplasm= 98; B cell ALL = 11, mixed phenotype leukemia = 1) and the cumulative incidence is increasing w/ time.”
Title: Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma
Authors: Binoy Yohannan, Benjamin Langworthy, Lindsey Turner, Angela Dispenzieri, Francis Buadi, David Dingli, Nelson Leung, Prashant Kapoor, Wilson Gonsalves, Taxiarchis Kourelis, Joselle Cook, Moritz Binder, Suzanne Hayman, Yi Lin, Ronald Go, Rahma Warsame, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar, Hassan Alkhateeb, William Hogan, Aasiya Matin, Mrinal Patnaik, Aref Al-Kali, Abhishek Mangaonkar, Hefazi Torghabeh, Robert Wolf, Mithun Shah, Morie Gertz
You can read the Full Article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
